-
Innovation Ranking
Innovation Ranking – AVEO Pharmaceuticals Inc
AVEO Pharmaceuticals Inc (AVEO), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rilogrotug in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rilogrotug in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rilogrotug in Metastatic Pancreatic Cancer Drug Details: AV-380 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rilogrotug in Cancer Anorexia-Cachexia Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rilogrotug in Cancer Anorexia-Cachexia Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rilogrotug in Cancer Anorexia-Cachexia Syndrome Drug Details: AV-380 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rilogrotug in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rilogrotug in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rilogrotug in Metastatic Colorectal Cancer Drug Details: AV-380 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMB-101 in Seizures
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMB-101 in Seizures report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMB-101 in Seizures Drug Details: BMA-101 is under development for the treatment...
-
Product Insights
NewBiodesix Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Biodesix Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Biodesix Inc (Biodesix) is a molecular diagnostics company which discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests in oncology for patients and doctors to enable precision medicine. These tests are used for early detection of diseases, diagnosis accuracy, disease monitoring and also provide improved therapeutic guidance for cancer patients. Biodesix’s product portfolio includes GeneStrat, a gene panel...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ficlatuzumab in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ficlatuzumab in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ficlatuzumab in Oropharyngeal Cancer Drug Details: Ficlatuzumab (AV-299, SCH 900105) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ficlatuzumab in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ficlatuzumab in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ficlatuzumab in Nasopharyngeal Cancer Drug Details: Ficlatuzumab (AV-299, SCH 900105) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ficlatuzumab in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ficlatuzumab in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ficlatuzumab in Recurrent Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib Hydrochloride in Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Renal Cell Carcinoma Drug Details: Tivozanib Hydrochloride...